Poland· PL-100537182
Enflonsia
A clesrovimab product containing clesrovimab, registered in Poland by Merck Sharp & Dohme B.V.. The same ATC class is registered in 11 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Clesrovimab is registered in 11 of 19 countries.
Countries holding a registration under ATC J06BD10 (clesrovimab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 9 of them publish a price we can compare per daily dose
Clesrovimab · ATC J06BD10
11 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Norwayprice
- Polandprice
- Switzerlandprice
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Clesrovimab
- Manufacturer
- Merck Sharp & Dohme B.V.
- Country
- Poland (PL)
- ATC code
- J06BD10
- ATC class
- Clesrovimab
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin00191778027051
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Clesrovimab in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaENFLONSIAMerck Sharp & Dohme B.V., Haarlem
- BelgiumEnflonsia 105 mgMerck Sharp & Dohme
- SpainENFLONSIA 105 MG SOLUCION INYECTABLE EN JERINGA PRECARGADAMerck Sharp & Dohme B.V.
- IcelandEnflonsiaMerck Sharp & Dohme B.V.*
- NorwayEnflonsiaMerck Sharp & Dohme B.V.
- SwedenEnflonsia 105 mg Injektionsvätska, lösning i förfylld sprutaMerck Sharp & Dohme BV
- SwitzerlandEnflonsia
- FinlandEnflonsiaMerck Sharp & Dohme B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Enflonsia
- Liechtenstein · Enflonsia
- Norway · Enflonsia
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/5b8373cf-404e-4b58-93b4-b4d1e81b8cbd GET /v1/drugs/5b8373cf-404e-4b58-93b4-b4d1e81b8cbd?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań w ampułko-strzykawce",
"source": "urpl",
"strength": "105 mg",
"packaging": "Rp ¦ EU/1/25/1984/001 ¦ 166844\n1 amp.-strzyk. 0,7 ml\nRp ¦ EU/1/25/1984/002 ¦ 166845\n1 amp.-strzyk. 0,7 ml ¦ 1 igła \n00191778027051 ¦ Rp ¦ EU/1/25/1984/003 ¦ 166846\n1 amp.-strzyk. 0,7 ml ¦ 2 igły \nRp ¦ EU/1/25/1984/004 ¦ 166847\n10 amp.-strzyk. 0,7 ml\nRp ¦ EU/1/25/1984/005 ¦ 166848\n10 amp.-strzyk. 0,7 ml ¦ 10 igieł \nRp ¦ EU/1/25/1984/006 ¦ 166849\n10 amp.-strzyk. 0,7 ml ¦ 20 igieł \nRp ¦ EU/1/25/1984/007 ¦ 166850\n50 amp.-strzyk. 5 opakowań po 10 ampułko-strzykawe - opakowanie zbiorcze",
"substance": "Klesrowimab 105 mg",
"common_name": "Clesrovimab",
"pl_product_id": "100537182",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about clesrovimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.